
    
      This is a multi-center observational study with both retrospective and prospective data
      collections to describe the effectiveness and safety of sequential dacomitinib and 3rd
      generation EGFR-TKI used in patients with EGFR mutation-positive NSCLC with T790M-aquired
      resistance in a clinical practice setting. The study will include patients who were or will
      be diagnosed as advanced NSCLC with EGFR mutation positive and received dacomitinib as
      first-line treatment followed by second-line 3rd generation EGFR-TKI treatment in multiple
      tertiary care hospitals after Sep 1st, 2019. Patients' clinical information prior to the
      study initiation in each hospital will be collected retrospectively through chart review.
      After the study initiation, new patient enrollment will last till Dec 2022. Patients'
      clinical care after the study initiation will be followed up prospectively until the end of
      study. The interval of response evaluation is recommended to be every 2 to 3 months in the
      treatment period and the interval of follow-up is recommended to be every 2 to 3 months in
      the post-treatment period till the end of study in the prospective data collection period.
    
  